Barclays PLC Makes New Investment in Kazia Therapeutics Limited (NASDAQ:KZIA)

Barclays PLC acquired a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $212,000.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on shares of Kazia Therapeutics in a research note on Thursday, February 6th. They set a “buy” rating and a $15.00 price objective on the stock.

Kazia Therapeutics Trading Down 1.7%

Shares of Kazia Therapeutics stock opened at $3.56 on Tuesday. Kazia Therapeutics Limited has a 12-month low of $2.86 and a 12-month high of $79.00. The firm’s 50-day moving average price is $4.00 and its two-hundred day moving average price is $11.09.

Kazia Therapeutics Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.